Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares Earnings Dividend

Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares’s revenue jumped 55.36% since last year same period to $243.6Mn in the Q2 2026. On a quarterly growth basis, Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares has generated 13.69% jump in its revenue since last 3-months.

Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares’s net profit jumped 42.62% since last year same period to $25.43Mn in the Q2 2026. On a quarterly growth basis, Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares has generated 12.57% jump in its net profits since last 3-months.

Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares’s net profit margin fell -8.2% since last year same period to 10.44% in the Q2 2026. On a quarterly growth basis, Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares has generated -0.98% fall in its net profit margins since last 3-months.

Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares’s earning per share (EPS) estimates for the current quarter stand at 0.31 - a 3.33% jump from last quarter’s estimates.

Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares’s earning per share (EPS) estimates for the current year stand at 0.31.

Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares’s earning per share (EPS) jumped 30.43% since last year same period to 0.3 in the Q2 2026. This indicates that the Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares has generated 30.43% annual rate of jump in its earning per share (EPS) in the last 4 quarters.